| 38.17 -0.33 (-0.86%) | 12-08 12:13 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 49.39 | 1-year : | 55.65 |
| Resists | First : | 42.29 | Second : | 47.65 |
| Pivot price | 41.3  |
|||
| Supports | First : | 33.63 | Second : | 27.98 |
| MAs | MA(5) : | 38.79 |
MA(20) : | 42.18 |
| MA(100) : | 31.92 |
MA(250) : | 0 | |
| MACD | MACD : | -0.6 |
Signal : | 0 |
| %K %D | K(14,3) : | 29.3 |
D(3) : | 36.2 |
| RSI | RSI(14): 40.5 |
|||
| 52-week | High : | 47.65 | Low : | 8.24 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MLYS ] has closed above bottom band by 10.6%. Bollinger Bands are 17.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 39.61 - 39.84 | 39.84 - 40.08 |
| Low: | 37 - 37.24 | 37.24 - 37.5 |
| Close: | 38.03 - 38.46 | 38.46 - 38.93 |
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mon, 08 Dec 2025
Mineralys Therapeutics, Inc. $MLYS Shares Purchased by Pale Fire Capital SE - MarketBeat
Sat, 06 Dec 2025
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Fri, 05 Dec 2025
Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet - Zacks Investment Research
Fri, 05 Dec 2025
Mineralys Therapeutics, Inc. $MLYS Shares Sold by Quadrature Capital Ltd - MarketBeat
Wed, 03 Dec 2025
Mineralys Therapeutics, Inc. $MLYS Shares Acquired by Geode Capital Management LLC - MarketBeat
Sat, 29 Nov 2025
A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital’s Major New Investment - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 79 (M) |
| Shares Float | 57 (M) |
| Held by Insiders | 1.4 (%) |
| Held by Institutions | 111.8 (%) |
| Shares Short | 6,890 (K) |
| Shares Short P.Month | 7,130 (K) |
| EPS | -2.93 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.3 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -26.5 % |
| Return on Equity (ttm) | -42.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -171 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -13.1 |
| PEG Ratio | 0 |
| Price to Book value | 5.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.66 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|